NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy.

Xia LiuPei-Pei WangGuolong Liu

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)

NRI and SIRI were the best combination models for predicting clinical outcomes of NSCLC patients receiving EGFR-TKI treatment, which may be a novel biomarker for supplement risk stratification in NSCLC patients.

Keyphrases

small cell lung cancer
tyrosine kinase
advanced non small cell lung cancer
epidermal growth factor receptor
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
brain metastases
replacement therapy